


**REMARKS**

Applicants request entry of this second Supplemental Amendment to correct minor errors in the amendment filed April 30, 2008. Applicants appreciate Examiner Covington's agreement, through telephonic communications with the undersigned on June 5, 2008, to consider the Amendment. Amendment has been made to claims 1, 2 and 15 to correct minor grammatical errors, changing "meanings" to meaning in claim 1, changing Arabic numeral 1 to Roman numeral I in claim 2, and deletion of "and" from claim 15.. No new matter has been added.



Furthermore, several highlighted areas of structural formulae submitted in the "Remarks" section of the Amendment filed April 30, 2008 did not print as intended due to computer incompatibilities. Accordingly, the remarks beginning on page 19, line 11 and ending on page 20, line 8, are set forth in proper form below. The only change is the location of the circled portions of the structures in the table.

--Incidentally, if the Applicants were required to present the structural formula closest to that of the above Xanthofulvin and a tautomer thereof, claim 1 [V] and claims 10-11, represented by formula (16), would be chosen:



In this case, the Examiner's attention is called to the benzene ring of the terminal end of the tricyclic part. The substituents on this ring are limited to three hydroxyl groups. In the above Xanthofulvin and a tautomer thereof, the corresponding substituents on the benzene ring in the tricyclic part are two hydroxyl groups and one carboxyl group, and in addition, the sites of substitution are different. In this respect, the compounds in the scope of the claims of the present application are different from the above Xanthofulvin and a tautomer thereof (see chemical formulae below, with the relevant portions circled for clarity). From this, it is obvious that the above Xanthofulvin and a tautomer thereof are not included in the scope of the claims of

the present application.


The scope of the claims of the present application	Xanthofulvin and a tautomer thereof
	

As stated above, Xanthofulvin and its tautomer are never included in the scope of claim 1 of the present application. Further, US Patent No. 5,229,123 of Masubuchi et al. does not teach or suggest the invention of claim 1 of the present application.--

Entry of this amendment and favorable reconsideration of the application are respectfully requested.

Respectfully submitted,

Date: 6/6/08

  
 Ann S. Hobbs, Ph.D.  
 Registration No. 36,830  
 VENABLE  
 P.O. Box 34385  
 Washington, D.C. 20043-9998  
 Telephone: (202) 344-4000  
 Telefax: (202) 344-8300